<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043313</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-017</org_study_id>
    <secondary_id>NCI-2017-01107</secondary_id>
    <secondary_id>ACCRU-GI-1617</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03043313</nct_id>
  </id_info>
  <brief_title>Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer</brief_title>
  <official_title>MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well the drug tucatinib works when given with trastuzumab and when
      given by itself. The participants in this trial have HER2-positive (HER2+) metastatic
      colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the
      body.

      In the first part of this study, participants enrolled into Cohort A and received both
      tucatinib and trastuzumab. In the second part of this study, participants are randomly
      assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and
      trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do
      not respond to therapy may have an option to receive tucatinib plus trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (cORR) per RECIST 1.1 per blinded independent central review (BICR) in pooled Cohorts A+B</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>cORR is defined as confirmed complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR at 12 weeks of treatment per RECIST 1.1 according to BICR assessment</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST 1.1 according to BICR assessment</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per RECIST 1.1 according to BICR assessment for pooled Cohorts A+B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>PFS is defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to first documentation of tumor progression or to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in pooled Cohorts A+B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>OS is defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modifications</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Tucatinib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Given intravenously (into the vein; IV)</description>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort C: Tucatinib Monotherapy</arm_group_label>
    <other_name>ARRY-380</other_name>
    <other_name>ONT-380</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically and/or cytologically documented adenocarcinoma of the colon or rectum
             that is metastatic and/or unresectable

          -  Unless contraindicated, participants must have received and failed regimens containing
             the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine),
             oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab,
             or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor
             has deficient mismatch repair proteins or is MSI-High.

          -  Have progression of unresectable or metastatic CRC after the last systemic therapy, or
             be intolerant of last systemic therapy

          -  Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS
             testing

          -  Willing and able to provide the most recent tissue blocks obtained prior to treatment
             initiation. If archival tissue is not available, then a newly-obtained baseline biopsy
             of an accessible tumor

          -  Have confirmed HER2-positive mCRC, as defined by having tumor tissue tested at a
             Clinical Laboratory Improvement Act (CLIA)-certified laboratory, meeting at least one
             of the following criteria:

               -  HER2+ overexpression (3+ immunohistochemistry [IHC])by an FDA-approved HER2 ICH
                  test

               -  HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved HER2 in situ
                  hybridization assay (FISH or chromogenic in situ hybridization [CISH]))

               -  HER2 (ERBB2) amplification by CLIA-certified next generation sequencing (NGS)
                  sequencing assay

          -  Have radiographically measurable disease assessable by RECIST 1.1, with at least one
             site of disease that is measurable and that has not been previously irradiated; or, if
             the participant has had previous radiation to the target lesion(s), there must be
             evidence of progression since the radiation

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2

          -  Life expectancy greater than 3 months

          -  Have adequate hematological, hepatic, renal, coagulation, and cardiac function

        Exclusion Criteria

          -  Previous treatment with anti-HER2 targeting therapy

          -  Previous treatment with any systemic anticancer therapy, non-central nervous system
             radiation, or experimental agent within 3 weeks of first dose of study treatment

          -  Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with
             the following exceptions:

               -  Alopecia and neuropathy, which must have resolved to ≤ Grade 2

               -  Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the
                  time of occurrence, and must have resolved completely

               -  Anemia, which must have resolved to ≤ Grade 2

               -  Decreased ANC, which must have resolved to ≤ Grade 2

          -  Have clinically significant cardiopulmonary disease

          -  Have known myocardial infarction, unstable angina, cardiac or other vascular stenting,
             angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment

          -  Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior
             to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or
             anticipation of need for major surgical procedure during the study

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Known to be positive for hepatitis B by surface antigen expression

          -  Known to have active hepatitis C infection

             o Exception for participants with a documented sustained virologic response of 12
             weeks

          -  Known to be positive for human immunodeficiency virus (HIV)

          -  Subjects who are pregnant, breastfeeding, or planning a pregnancy

          -  Inability to swallow pills or any significant gastrointestinal disease which would
             preclude the adequate oral absorption of medications

          -  Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a
             CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment

          -  History of another malignancy within 3 years before the first dose of study drug, or
             any evidence of residual disease from a previously diagnosed malignancy.

             o Exceptions are malignancies with a negligible risk of metastasis or death

          -  Subjects with known active CNS metastasis o Irradiated or resected lesions are
             permitted, provided the lesions are fully treated and inactive, subject is
             asymptomatic, and no steroids have been administered for at least 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Strickler</last_name>
    <role>Study Chair</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Stecher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Araque</last_name>
      <phone>480-301-2048</phone>
      <email>Bekaii-saab.tanios@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Heritage Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Cordes</last_name>
      <phone>707-521-3830</phone>
      <email>Kayla.cordes@stjoe.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Young</last_name>
      <phone>707-521-3830</phone>
      <email>Kimberly.Young@stjoe.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South Region</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Bentz</last_name>
      <phone>941-363-5713</phone>
      <email>lbentz@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>William Harwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Simonetta</last_name>
      <phone>727-821-0017</phone>
      <email>msimonetta@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunisha Thomas</last_name>
      <phone>404-778-1900</phone>
      <email>sunisha.thomas@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Christina Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex (Ryan) El-Naggar</last_name>
      <phone>773-702-7763</phone>
      <email>relnaggar@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayra Thompson</last_name>
      <phone>913-588-6029</phone>
      <email>kthompson8@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Anwaar Saeed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Gisondi</last_name>
      <phone>617-724-4000</phone>
      <email>AGISONDI@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kimmie Ng, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Masnyk</last_name>
      <phone>617-632-3000</phone>
      <email>Larissa_Masnyk@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kimmie Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Hamann</last_name>
      <phone>507-284-0923</phone>
      <email>Hamann.Lucas@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Joleen Hubbard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hicks</last_name>
      <phone>716-845-8556</phone>
      <email>Karen.Hicks@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Christos Fountzilas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Weiss</last_name>
      <phone>646-227-3010</phone>
      <email>WeissJ2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Andrea Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ireka Burrus</last_name>
      <phone>919-668-1861</phone>
      <email>ireka.burrus@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John Strickler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hovanec</last_name>
      <phone>216-844-8573</phone>
      <email>Brenda.hovanec@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>David Bajor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Taber</last_name>
      <phone>503-494-3606</phone>
      <email>tabere@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Adel Kardosh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luann Healy</last_name>
      <phone>412-359-6147</phone>
      <email>Luann.Healy@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Gene Finley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Baker</last_name>
      <email>Rita.Baker@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Salas</last_name>
      <phone>806-725-8000</phone>
      <email>ssalas@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Isaac Tafur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Leary</last_name>
      <phone>801-213-8429</phone>
      <email>ashley.leary@hci.utah.etu</email>
    </contact>
    <investigator>
      <last_name>Ignacio Garrido-Laguna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Park</last_name>
      <phone>206-606-6439</phone>
      <email>parks@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Coveler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Morrow</last_name>
      <phone>414-646-9826</phone>
      <email>Kevin.Morrow@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Federico Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>ERBB2</keyword>
  <keyword>Colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

